Printer Friendly

GLYNASE PRESTAB TABLETS RECEIVE THREE-YEAR MARKETING PROTECTION

 GLYNASE PRESTAB TABLETS RECEIVE THREE-YEAR MARKETING PROTECTION
 KALAMAZOO, Mich., May 13 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Glynase PresTab Tablets (glyburide 1.5 mg and 3 mg) three-year protection against the approval of any abbreviated new drug applications (ANDAs) for 1.5 or 3 mg glyburide formulations, The Upjohn Company (NYSE: UPJ) announced today.
 Under the terms of the Drug Price Competition and Patent Term Restoration Act of 1984, Upjohn and Hoechst-Roussel Pharmaceuticals, Inc., received protection until March 4, 1995, for their jointly developed 1.5 and 3 mg glyburide formulations.
 Only if another company successfully completes clinical studies and files a full new drug application (NDA) can it be granted approval to market a 1.5 or 3 mg glyburide formulation before that date.
 Glynase PresTab is an improved formulation of glyburide, the most widely used oral medication in the United States for non-insulin- dependent diabetes, which affects an estimated 14 million Americans.
 "We are pleased with the additional protection this provides Glynase PresTab," said Ley S. Smith, vice chairman of the board, The Upjohn Company. "Formulation and tablet design patents provide exclusivity in the covered areas until 2004, but the FDA action expands the product's protection until 1995. Because of the amount of work Upjohn committed to human studies of the new Glynase PresTab Tablets, we especially value this protection."
 Glynase PresTab Tablets were cleared for marketing March 4 and are being introduced this month. Their improved bioavailability (drug delivery) provides doctors and patients with an optimum glyburide formulation. Glynase PresTab is not interchangeable with previous formulations of glyburide; doctors will need to determine the appropriate dosage of Glynase PresTab based upon patients' blood sugar levels. The Glynase PresTab tablet has been designed to facilitate this titration by breaking in half easily and evenly if dosage needs to be increased or decreased.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 5/13/92
 /CONTACT: Jan R. AufderHeide of The Upjohn Company, 616-323-6546/
 (UPJ) CO: The Upjohn Company ST: Michigan IN: MTC SU:


ML -- DE022 -- 9757 05/13/92 14:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1992
Words:382
Previous Article:CONTINENTAL MORTGAGE AND EQUITY TRUST REPORTS FIRST QUARTER RESULTS
Next Article:STATEMENT BY RICHARD H. JENRETTE, EQUITABLE CHAIRMAN & CEO, ON THE AFFIRMATIVE RULING BY THE NEW YORK SUPERINTENDENT OF INSURANCE
Topics:


Related Articles
GLYNASE PRESTAB TABLETS CLEARED FOR MARKETING FOR NON-INSULIN-DEPENDENT DIABETES
COPLEY PHARMACEUTICAL, INC. RECEIVES FDA APPROVAL FOR ATENOLOL TABLETS, 50MG AND 100MG
COPLEY PHARMACEUTICAL, INC. ANNOUNCES FIRST QUARTER RESULTS
Clarification: Copley's Micronized Glyburide Is AB Rated, Therapeutically Equivalent To Glynase
Pharmacia & Upjohn Acquires Rights to Antidiabetes Compound
Pharmacia & Upjohn to Acquire Rights to Market Miglitol for Type II Diabetes
Sulfonylureas. (Medication Update).

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters